Key result
Cilostazol treatment in diabetic rats effectively prevented pathological kidney changes and significantly lowered TSP-1 and TGF-beta expression compared with untreated diabetic rats.
Why the study?
Does cilostazol reduce TSP-1 and TGF-beta expression and prevent pathological kidney changes in rats with streptozotocin-induced diabetes?
Does cilostazol reduce TSP-1 and TGF-beta expression and prevent pathological kidney changes in rats with streptozotocin-induced diabetes?
Cilostazol demonstrates renal protective effects in a diabetic rat model, potentially mediated through the down-regulation of TSP-1 and TGF-beta expression.
Hypothesis-generating for cilostazol renoprotection in diabetes; human trials needed before any clinical consideration.
Diabetic nephropathy is a major complication facing patients with diabetes mellitus. The renal protective effects of the phosphodiesterase III inhibitor, cilostazol, were investigated in rats with streptozotocin-induced diabetes. Expression of thrombospondin-1 (TSP-1) and transforming growth factor-beta (TGF-beta) in the kidney was measured by immunohistochemistry and real-time reverse transcription-quantitative polymerase chain reaction analysis in diabetic rats, cilostazol-treated diabetic rats and control rats. Ultrastructural changes in the kidney were also analysed using microscopy. Four weeks after the induction of diabetes, TSP-1 and TGF-beta expression was significantly increased in the kidneys of diabetic rats compared with the control and was significantly lower in cilostazol-treated diabetic rats than in the untreated diabetic rats. Microscopy revealed characteristic renal pathology in the diabetic group, which was rarely seen in the cilostazol-treated diabetic rats. In conclusion, this study indicates that cilostazol treatment of diabetic rats effectively prevents pathological kidney changes, possibly via the down-regulation of TSP-1 and TGF-beta expression compared with untreated rats.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2009) studied Diabetic nephropathy. Cilostazol vs. Untreated diabetic rats and control rats was evaluated on Expression of thrombospondin-1 (TSP-1) and transforming growth factor-beta (TGF-beta) and ultrastructural changes in the kidney. Cilostazol treatment in diabetic rats effectively prevented pathological kidney changes and significantly lowered TSP-1 and TGF-beta expression compared with untreated diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: